After months of horse-trading, hand-wringing, and heated debate, the $74 billion merger of Bristol-Myers Squibb and Celgene (CELG) was finally approved by shareholders on Friday. “We’re very excited about the new company,” Giovanni Caforio, Bristol’s chairman and CEO, said at the meeting.

Now what?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • CELG lost their spectacular leadership, when appointing Mark Alles
    as CEO. They by passed Jackie Fouse’ , COO , President and most
    important entrepreneurial , Sell Side favorite person in management,
    so they could appoint a bright guy , Mark Alles who didn’t have CEO ability. The very costly Mongersen deal for a PH I/II Italian asset with no proof of concept . Alles as CEO obviously didn’t read the electronic NDA filing and missed the absence of Pre Clinical Data on Ozanimod as well as its Metabolite. This is the most costly blunder in Biotech History, costing the Company 70% of its market cap and its independent status. Now the BMY rescue. I believe Giovanni Caforio (CEO) and Tom Lynch (CSO) of BMY will allow for the creation of an Oncology Giant. I would own the CVR, as the chance of it paying off is high, IMHO. First time in my 25 years in the sector that such a horrendous blunder created a Giant Merger. My $.02 worth.

  • The marriage has not happened yet. Only the BMS shareholders have approved the merger.

    I suggest the following name: Bristolgene Squibbcel !!!!

    • Actually both Celgene and Brystol Myers Squibb shareholders approved the merger today. The former did so with around 70% of votes in favor, the latter with around 75%. Its a done deal.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy